Trials / Completed
CompletedNCT00336479
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 263 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Telaprevir | tablet |
| DRUG | Ribavirin | tablet |
| DRUG | Pegylated Interferon Alfa 2a | Solution for injection |
| OTHER | Placebo | matching placebo tablet |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2006-06-13
- Last updated
- 2014-07-23
- Results posted
- 2011-07-21
Locations
37 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT00336479. Inclusion in this directory is not an endorsement.